400 related articles for article (PubMed ID: 29807291)
1. Relapse after treatment withdrawal of antiepileptic drugs for Juvenile Absence Epilepsy and Juvenile Myoclonic Epilepsy.
Healy L; Moran M; Singhal S; O'Donoghue MF; Alzoubidi R; Whitehouse WP
Seizure; 2018 Jul; 59():116-122. PubMed ID: 29807291
[TBL] [Abstract][Full Text] [Related]
2. Seizure outcome in 175 patients with juvenile myoclonic epilepsy--a long-term observational study.
Höfler J; Unterberger I; Dobesberger J; Kuchukhidze G; Walser G; Trinka E
Epilepsy Res; 2014 Dec; 108(10):1817-24. PubMed ID: 25443450
[TBL] [Abstract][Full Text] [Related]
3. Antiepileptic drug withdrawal in juvenile myoclonic epilepsy.
Syvertsen M; Fløgstad I; Enger U; Landmark CJ; Koht J
Acta Neurol Scand; 2019 Feb; 139(2):192-198. PubMed ID: 30378684
[TBL] [Abstract][Full Text] [Related]
4. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.
Prasad A; Kuzniecky RI; Knowlton RC; Welty TE; Martin RC; Mendez M; Faught RE
Arch Neurol; 2003 Aug; 60(8):1100-5. PubMed ID: 12925366
[TBL] [Abstract][Full Text] [Related]
5. Clinical heterogeneity of juvenile myoclonic epilepsy: follow-up after an interval of more than 20 years.
Syvertsen MR; Thuve S; Stordrange BS; Brodtkorb E
Seizure; 2014 May; 23(5):344-8. PubMed ID: 24512779
[TBL] [Abstract][Full Text] [Related]
6. Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Syvertsen M; Baftiu A; Enger U; Koht J; Johannessen SI
Epilepsy Behav; 2019 Sep; 98(Pt A):110-116. PubMed ID: 31330379
[TBL] [Abstract][Full Text] [Related]
7. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
Cação G; Parra J; Mannan S; Sisodiya SM; Sander JW
Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Chowdhury A; Brodie MJ
Epilepsy Res; 2016 Jan; 119():62-6. PubMed ID: 26675554
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E
Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of higher drug load for seizure freedom in idiopathic generalized epilepsy: Comparison between juvenile myoclonic epilepsy and other types.
Kitazawa Y; Jin K; Kakisaka Y; Fujikawa M; Tanaka F; Nakasato N
Epilepsy Res; 2018 Aug; 144():20-24. PubMed ID: 29729533
[TBL] [Abstract][Full Text] [Related]
11. Focal EEG features and therapeutic response in patients with juvenile absence and myoclonic epilepsy.
Japaridze G; Kasradze S; Lomidze G; Zhizhiashvili L; Kvernadze D; Geladze K; Beniczky S
Clin Neurophysiol; 2016 Feb; 127(2):1182-1187. PubMed ID: 26712538
[TBL] [Abstract][Full Text] [Related]
12. Antiepileptic drugs withdrawal in patients with idiopathic generalized epilepsy.
Pavlović M; Jović N; Pekmezović T
Seizure; 2011 Sep; 20(7):520-5. PubMed ID: 21493107
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome in adolescent-onset generalized genetic epilepsies.
Vorderwülbecke BJ; Kowski AB; Kirschbaum A; Merkle H; Senf P; Janz D; Holtkamp M
Epilepsia; 2017 Jul; 58(7):1244-1250. PubMed ID: 28464258
[TBL] [Abstract][Full Text] [Related]
14. School performance and psychiatric comorbidity in juvenile absence epilepsy and juvenile myoclonic epilepsy: a Danish population-based cohort study.
Boesen MS; Børresen ML; Christensen SK; Klein-Petersen AW; El Mahdaoui S; Sagar MV; Schou E; Eltvedt AK; Miranda MJ; Born AP; Uldall PV; Thygesen LC; Cacic Hribljan M
J Neurol; 2022 Sep; 269(9):4997-5007. PubMed ID: 35595971
[TBL] [Abstract][Full Text] [Related]
15. Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy.
Komatsubara T; Kobayashi Y; Hiraiwa A; Magara S; Hojo M; Ono T; Okazaki K; Fukuda M; Tohyama J
Epilepsia Open; 2022 Jun; 7(2):332-343. PubMed ID: 35445562
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy.
Wirrell E; Camfield C; Camfield P; Dooley J
Epilepsia; 2001 Jun; 42(6):760-3. PubMed ID: 11422332
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors.
Senf P; Schmitz B; Holtkamp M; Janz D
Neurology; 2013 Dec; 81(24):2128-33. PubMed ID: 24212391
[TBL] [Abstract][Full Text] [Related]
18. Concepts and controversies of juvenile myoclonic epilepsy: still an enigmatic epilepsy.
Koepp MJ; Thomas RH; Wandschneider B; Berkovic SF; Schmidt D
Expert Rev Neurother; 2014 Jul; 14(7):819-31. PubMed ID: 24931665
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI
Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184
[TBL] [Abstract][Full Text] [Related]
20. Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors.
Stevelink R; Koeleman BPC; Sander JW; Jansen FE; Braun KPJ
Eur J Neurol; 2019 Jun; 26(6):856-864. PubMed ID: 30223294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
